Bellicum Pharmaceuticals

173 articles about Bellicum Pharmaceuticals

• Bellicum Pharmaceuticals, Inc. Appoints Baylor College of Medicine's David M. Spencer as Chief Scientific Officer

  4/12/2012

• Bellicum Pharmaceuticals, Inc. Closes $20 Million Series B Financing

  3/8/2012

• Bellicum Pharmaceuticals, Inc. Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients

  11/3/2011

• Bellicum Pharmaceuticals, Inc. Awarded $5.7 Million by the Cancer Prevention and Research Institute of Texas

  3/25/2011

• Bellicum Pharmaceuticals, Inc. Release: Clinical Responses Demonstrated in Metastatic Castrate Resistant Prostate Cancer Patients Treated With BPX-101 Cancer Vaccine in Phase I/II Study

  2/18/2011

• Bellicum Pharmaceuticals, Inc. Announces $3 Million in Convertible Note Funding

  12/21/2010

• Bellicum Pharmaceuticals, Inc. Announces World Renowned Clinical Advisory Board Appointments

  11/10/2010

• Bellicum Pharmaceuticals, Inc. Systemic and Antigen-Specific Immune Responses in Patients Treated With Cancer Vaccine BPX-101 Correlate With Clinical Response Interim Phase I/II Results Presented at American Association for Cancer Research 2010 Annual Mee

  4/19/2010

• Bellicum Pharmaceuticals, Inc. Raises $4.5 Million

  11/2/2009

• Bellicum Pharmaceuticals, Inc. Announces $4.5 Million in New Funding

  10/27/2009

• Bellicum Pharmaceuticals, Inc. Announces $3.75 Million in Financing

  10/10/2007

• Bellicum Pharmaceuticals, Inc. Announces Commercial Licensing Of Ariad Pharmaceuticals, Inc.'s ARGENT(TM) Cell-Signaling Regulation Technology For Development Of New Cancer Therapies

  10/11/2006

• Ariad Pharmaceuticals, Inc. Grants Commercial License To Its Patented ARGENT(TM) Cell-Signaling Regulation Technology For Development Of New Cancer Therapies

  10/11/2006